Search
rolapitant (Varubi)
Indication:
- prevention of delayed-phase nausea & vomiting in adults undergoing chemotherapy
- intended to be taken in combination with other antiemetics Pharmkacokinetics:
- inhibits the CYP2D6
Adverse effects:
- common
- neutropenia, hiccups, anorexia, dizziness
Drug interactions:
- may increase levels of drugs metabolized by CYP2D6
- thioridazine
Mechanism of action:
- substance P receptor antagonist
General
anti-emetic
Database Correlations
PUBCHEM correlations
References
- FDA News Release. Sept. 2, 2015
FDA approves new drug treatment for nausea and vomiting from
chemotherapy.
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm460838